PE-22-28 vs N-Acetyl-Semax
Side-by-side comparison of PE-22-28 and N-Acetyl-Semax: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
PE-22-28
N-Acetyl-Semax
PE-22-28
PE-22-28 is a synthetic seven-amino-acid peptide (sequence PAGASRLLLLTGEIDLP derivative, commonly truncated to PE-22-28 as shorthand for "position 22-28" within the parent humanin-family sequence) that was designed as an…
Lowest listed price: $54.99 across 1 listing
Full PE-22-28 profileN-Acetyl-Semax
This is a duplicate/alias entry. The full, maintained guide for this compound lives at NA-Semax (/compound/na-semax). See that page for mechanism, dosing, evidence, and safety.
No vendor price on file.
Full N-Acetyl-Semax profileSide-by-side comparison
| Attribute | PE-22-28 | N-Acetyl-Semax |
|---|---|---|
| Category | Nootropics | Cognitive |
| Research Stage | Preclinical | Duplicate entry - see NA-Semax |
| Mechanism of Action | PE-22-28 is a synthetic 7-amino-acid peptide (sequence GVSWGLR) and a shortened analog of spadin. Its proposed mechanism is inhibition of the TREK-1 (TWIK-related K+) channel, a two-pore-domain potassium channel (K2P2.1 / KCNK2) implicated in mood regulation.… | See the full guide This page is a duplicate of NA-Semax, which is the canonical, maintained entry. To avoid conflicting or outdated information, all detail - mechanism of action, protocols, dosing, side effects, and verified citations - is kept on that single… |
| Half-Life | Not characterized in humans. As a small 7-amino-acid peptide a short plasma half-life is expected; in mice the parent peptide spadin lost antidepressant activity by about 7 hours after a single dose, while modified analogs (e.g., G/A-PE 22-28) extended the behavioral effect to roughly 21-23 hours [PMID:28955242]. | — |
| Typical Dose Range | 250-2000 mcg subcutaneous per dose (empirical research-chemical community range; no clinically validated human dose exists; effective preclinical rodent doses were far lower, ~3 mcg/kg). | — |
| Dosing Frequency | Once daily or every other day (research-chemical community protocols; no validated clinical dosing schedule). | — |
| Administration | — | — |
| Side Effects | No human side-effect data exist for PE-22-28 because it has never been tested in people. What can be said comes from rodent studies of PE-22-28, spadin and their analogs, plus general considerations for injected research peptides. In the preclinical work, the… | — |
| Molecular Weight | 773.9 g/mol | — |
| Common Vial Sizes | — | — |
Price tracking
PE-22-28: potential benefits
- Antidepressant-like effects in rodent models of depression (preclinical only)
- Potent, selective inhibition of the TREK-1 (K2P2.1) potassium channel (IC50 ~0.12 nM)
- Rapid-onset (~4-day) antidepressant profile in animals, unlike the multi-week lag of SSRIs
- Increased hippocampal neurogenesis in mice
- Increased cortical synaptogenesis (PSD-95) and BDNF expression in preclinical studies
- No human-validated benefits; not approved for any use (research use only)
N-Acetyl-Semax: potential benefits
- See the full guide at NA-Semax (/compound/na-semax) for benefits and evidence.
Frequently asked
What's the difference between PE-22-28 and N-Acetyl-Semax?
PE-22-28 is a nootropics that pe-22-28 is a synthetic 7-amino-acid peptide (sequence gvswglr) and a shortened analog of spadin. its proposed mechanism is inhibition of the trek-1 (twik-related k+) channel, a…. N-Acetyl-Semax is a cognitive that see the full guide this page is a duplicate of na-semax, which is the canonical, maintained entry. to avoid conflicting or outdated information, all detail - mechanism of action,…. The two differ in mechanism, half-life (Not characterized in humans. As a small 7-amino-acid peptide a short plasma half-life is expected; in mice the parent peptide spadin lost antidepressant activity by about 7 hours after a single dose, while modified analogs (e.g., G/A-PE 22-28) extended the behavioral effect to roughly 21-23 hours [PMID:28955242]. vs not reported), and typical dose range.
Which has the longer half-life, PE-22-28 or N-Acetyl-Semax?
PE-22-28 has a half-life of Not characterized in humans. As a small 7-amino-acid peptide a short plasma half-life is expected; in mice the parent peptide spadin lost antidepressant activity by about 7 hours after a single dose, while modified analogs (e.g., G/A-PE 22-28) extended the behavioral effect to roughly 21-23 hours [PMID:28955242].. N-Acetyl-Semax has a half-life of not reported. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Can you stack PE-22-28 and N-Acetyl-Semax?
Stacking depends on mechanism overlap, safety profile, and goals. PE-22-28 and N-Acetyl-Semax should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy PE-22-28 or N-Acetyl-Semax
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. Every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.